C
현대사료
016790KOSDAQ동물용 사료 및 조제식품 제조업44.5 / 100
Reference Date: 2026-06-10
Financial Score12.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is low with sound financial health but PER raises overvaluation concerns. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Hyundai Sahyo expanded its biotechnology business by acquiring LS L&C in 2023, focusing on developing the ovarian cancer treatment candidate 'Oregovomab'. The company emphasizes immunotherapy research amid the pharmaceutical industry's high entry barriers and growth potential, temporarily pausing its metastatic breast cancer pipeline. It concurrently operates a feed business alongside its biotech initiatives.
Number of Employees
68people
Average Salary
56.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
43.22Industry Average 9.090.0Point
4.8x industry avg (risky)
PBR
2.45Industry Average 0.580.0Point
4.2x industry avg (risky)
ROE
5.30Industry Average 6.302.5Point
Below industry avg
Debt Ratio
11.45Industry Average 11.594.0Point
In line with industry avg
Trend 2023~20255.5 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼16.0% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲107.8% (2-year basis)
ROE Trend
2.5 / 4
Avg ROE 555.8% (declining, 2yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position4.0Point
52w mid range (50%)
Current 994Won52-week high 99452-week low 994
1-month return3.0Point
1m 0% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-06-02
- Neutral[기재정정]투자판단관련주요경영사항 (주식가압류해제)2026-06-01
- Neutral[기재정정]투자판단관련주요경영사항 (주식가압류해제신청)2026-06-01
- Neutral분기보고서 (2026.03)2026-05-15
- Neutral기타시장안내 (개선계획 이행내역서 제출)2026-05-12